Key result
Concurrent fills for antihypertensive and BP-elevating medications rise ~16% from 2017 to 2023.
Why the study?
Many medications have blood pressure-elevating effects that might negatively impact blood pressure control, but trends in their prescription fills alongside antihypertensive medications among US individuals were unknown.
Observational
Yes
Concurrent prescription fills for BP-elevating and antihypertensive medications have increased in the US from 2017 to 2023, highlighting a need for careful medication selection in hypertensive patients.
May prompt closer medication review in hypertension; leaves open effects on BP control and outcomes.
BACKGROUND: Many medications can have blood pressure (BP)–elevating effects, which might negatively impact BP control among people with hypertension. This study examines trends in prescription fills for BP-elevating and antihypertensive medications, individually and concurrently, among US individuals. METHODS: Quarterly trends of individual and concurrent fills for BP-elevating and antihypertensive medications were reported using the nationwide sample from IQVIA’s Total Patient Tracker database, covering 94% of all retail prescription fills in the United States. We identified 1387 products containing BP-elevating medications and 240 products containing antihypertensive medications. Percentage change from Q1/2017 and average quarterly percent change from the joinpoint regression were used to present trends overall and by sex and age group (0–17, 18–44, 45–64, 65–74, and ≥75 years). RESULTS: From 2017 to 2023, fills remained stable for BP-elevating medications alone and increased for antihypertensive medications alone (9.5% increase; from 10.1% to 11.0%; P <0.001). Concurrent fills for antihypertensive and BP-elevating medications increased by 15.9% (from 5.4% to 6.2%; P <0.001). Fills for BP-elevating medications were higher among adult women compared with men; among women aged 18 to 44 years, this was primarily due to the use of combined oral contraceptives. In Q4/2023, fills for BP-elevating medications were most common among those aged 65 to 74 years (women=30.7%; men=20.4%). CONCLUSIONS: These results provide the first nationwide trends in concurrent prescription fills for BP-elevating and antihypertensive medications, indicating an increasing trend. Our findings might inform clinician decision-making regarding medication selection for patients with hypertension.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2025) conducted an observational in Hypertension. BP-elevating and antihypertensive medications was evaluated on Concurrent fills for antihypertensive and BP-elevating medications (15.9% increase, p=<0.001). Concurrent prescription fills for antihypertensive and BP-elevating medications in the US increased by 15.9% (from 5.4% to 6.2%; P<0.001) between 2017 and 2023.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: